alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
No. 82-749.

#### Baraban *v.*United States.

C. A. 11th Cir. Certiorari denied.
```

[Congressional Record Volume 155, Number 3 (Thursday, January 8, 2009)]
[Senate]
[Page S208]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

                         MESSAGE FROM THE HOUSE

  At 2:38 p.m., a message from the House of Representatives, delivered 
by Mr. Zapata, one of its reading clerks, announced that the House has 
passed the following bills, in which it requests the concurrence of the 
Senate:

       H.R. 35. An act to amend chapter 22 of title 44, United 
     States Code, popularly known as the Presidential Records Act, 
     to establish procedures for the consideration of claims of 
     constitutionally based privilege against disclosure of 
     Presidential records.
       H.R. 36. An act to amend title 44, United States Code, to 
     require information on contributors to Presidential library 
     fundraising organizations.

                          ____________________
```
EXHIBIT 11.1

 

                                                OMNIPOINT CORPORATION

                                      STATEMENT OF COMPUTATION OF LOSS PER SHARE

                                        ( In thousands, except per share data)

<TABLE>
<CAPTION>

                                                  Three Months Ended June 30,               Six Months Ended June 30,
                                                          (unaudited)                              (unaudited)
                                               -----------------------------------      ----------------------------------
                                                    1997                1996                 1997              1996
                                               ----------------    ---------------      ----------------  ----------------
                                            
Calculation of primary loss per share:
<S>                                            <C>                 <C>                  <C>               <C>        
      Net loss                                     $  (68,306)       $  (21,510)           $  (120,669)      $  (37,413)
                                               ================    ===============      ================  ================
Common shares outstanding                               51,457             45,620                51,367            43,045
                                               ----------------    ---------------      ----------------  ----------------
      Total shares - primary                            51,457             45,620                51,367            43,045
                                               ================    ===============      ================  ================
Primary loss per share:
      Net loss per share                           $     (1.33)      $      (0.47)          $     (2.35)     $      (0.87)
                                               ================    ===============      ================  ================



Note:     The computation of fully diluted earnings per share is identical to that of primary earnings per share for
          the periods presented above and therefore is not included separately herein.

</TABLE>
                                    
<PAGE>
### Leah Zorrilla, PhD Investigative Toxicology Division Integrated Laboratory Systems (ILS), Inc.



# Conduct and Performance of the In Vivo Mammalian EDSP Screening Assays

## Discuss In Vivo Conduct and Performance

Recent EDSP Experience

• 18 Uterotrophic Assays

• 21 Hershberger Bioassays

• 11 Female Pubertal Assays

• 10 Male Pubertal Assays

• Over 30 Range Finding AssaysVehicle Selection

• Solubility of Test Substances

• S tability Studies for Dose Formulations (~20 days)

Dose Selection

• Range Finding Studies were necessary to ensure MTD as described in Guidelines was achieved

• Body weight, clinical observations, liver/kidney weights

• Interpretation of definitive study is difficult when overt toxicity is exhibitedPerformance Criteria

• Use Facility Historical Data in addition to Guideline criteria

Weigh and retain liver for potential evaluation

• Enzyme Induction

Clinical Chemistry Data

• Is the complete panel useful and/or necessary if a range finder is performed?

• In our experience, no additional information was obtained from this data, cost not necessary (~$6k)

Statistical Analysis

• Clarification required for ANCOVA analyses (PND 21 vs. 22/23)Maximum Tolerated Dose Levels

• Definition of MTD in Guidelines “select doses that ensure animal survival and that are without significant toxicity or distress to the animals”

• Definition in white paper “Highest dose level be at or just below the MTD but need not exceed the limit dose (1000 mg/kg/day); however, typically, the agency also considered the toxicity profile of the chemical ( i.e., ≥10% decrease in body weight
, cholinesterase inhibition, target organ toxicity, etc .) in dose selection.”

Dose level of EE in OVX model

• Administration by oral gavage in OVX not part of validation studies; effective dose much higher than in immature
Performance criteria easily met for both modelsStudy Conduct Considerations

• Age at Castration

- confirm the animals are sexually mature prior to castration

• Weigh and retain liver for potential analysis due to induction of hepatic enzymes

Performance criteria easily met for androgen/ antiandrogen assaysMajor challenges included: Time/Dose Selection

• Conducting dose formulation stability testing

• Additional resources involved in conducting range finding studies for all mammalian in vivo assays for selection of a high dose that would not exceed MTD



### Deadlines for submission needs to consider these time and resource constraints for future test orders
**Exhibit
      13.2**




**18
      U.S.C. SECTION 1350**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**




In
      connection with the Annual Report of Prana Biotechnology Limited (the “Company”)
      on Form 20-F/A for the period ending June 30, 2006, as filed with the Securities
      and Exchange Commission on the date hereof (the “Report”), I, Richard Revelins,
      Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350,
      as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:




(1)
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and




(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and result of operations of the Company.




/s/ Richard
              Revelins*Richard
              RevelinsChief Financial Officer




June
      18,
      2007




*  The
      originally executed copy of this Certification will be maintained at the
      Company’s offices and will be made available for inspection upon
      request.
No. 86-5819.

No. 86-5833.

No. 86-5901.

No. 86-6061.

#### Peterkin *v.*Pennsylvania et al. Bevins *v.*Kentucky. Fugitt *v.*Georgia. Romero *v.*Texas.

Sup. Ct. Pa.;

Sup. Ct. Ky.;

Sup. Ct. Ga.; and

Ct. Crim. App. Tex. Certiorari denied. Reported below: No. 86-5819, 511 Pa. 299, 513 A. 2d 373; No. 86-5833, 712 S. W. 2d 932; No. 86-5901, 256 Ga. 292, 348 S. E. 2d 451; No. 86-6061, 716 S. W. 2d 519.

Justice Brennan and Justice Marshall,

dissenting.

Adhering to our views that the death penalty is in all circumstances cruel and unusual punishment prohibited by the Eighth and Fourteenth Amendments, *Gregg*v. *Georgia,*428 U. S. 153, 227, 231 (1976), we would grant certiorari and vacate the death sentences in these cases.
Exhibit 32.1 Certification by the Chief Executive Officer pursuant to 18 U.S.C. 1350
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  In connection with the Quarterly Report of PhytoMedical Technologies, Inc. (the Company) on the Form 10-Q for the period ending March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Greg Wujek, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:  (i) the Report filed by the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (ii) The information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of the Company on the dates and for the periods presented therein.  PHYTOMEDICAL TECHNOLOGIES, INC.Date: May 14, 2008By:/s/ Greg WujekGreg Wujek
President and Chief Executive Officer  This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
<PAGE>
                                                                    EXHIBIT 23.1

            Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements
(Form S-3 No. 333-120302 and Form S-8 Nos. 333-120579 and 333-110085) of
CancerVax Corporation and in the related Prospectuses of our reports dated March
4, 2005, with respect to: (1) the consolidated financial statements of CancerVax
Corporation, and (2) management's assessment of the effectiveness of internal
control over financial reporting, and the effectiveness of internal control over
financial reporting of CancerVax Corporation, included in this Annual Report
(Form 10-K) for the year ended December 31, 2004.

                                        /s/ Ernst & Young LLP

San Diego, California
March 14, 2005
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1417 Introduced in House (IH)]

<DOC>

115th CONGRESS
  1st Session
                                H. R. 1417

To amend the National Law Enforcement Museum Act to allow the Museum to 
   acquire, receive, possess, collect, ship, transport, import, and 
               display firearms, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 7, 2017

  Mr. Young of Alaska (for himself and Mr. McClintock) introduced the 
    following bill; which was referred to the Committee on Natural 
                               Resources

_______________________________________________________________________

                                 A BILL

 
To amend the National Law Enforcement Museum Act to allow the Museum to 
   acquire, receive, possess, collect, ship, transport, import, and 
               display firearms, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``National Law Enforcement Museum 
Exhibits Act''.

SEC. 2. AUTHORITY OF NATIONAL LAW ENFORCEMENT MUSEUM TO ACQUIRE, 
              RECEIVE, POSSESS, COLLECT, SHIP, TRANSPORT, IMPORT, AND 
              DISPLAY FIREARMS.

    The National Law Enforcement Museum Act (Public Law 106-492) is 
amended by adding at the end the following:

``SEC. 5. AUTHORITY OF MUSEUM TO ACQUIRE, RECEIVE, POSSESS, COLLECT, 
              SHIP, TRANSPORT, IMPORT, AND DISPLAY FIREARMS.

    ``(a) In General.--Notwithstanding any other provision of Federal 
law, or any law or any rule or regulations of a State or any political 
subdivision thereof, the Museum may acquire, receive, possess, collect, 
ship, transport, import, and display firearms (as defined in section 
921(a)(3) of title 18, United States Code, or section 5845(a) of the 
Internal Revenue Code of 1986) in fulfilling the purposes of the 
Museum.
    ``(b) Definition of State.--In subsection (a), the term `State' 
means the several States, the District of Columbia, Puerto Rico, the 
United States Virgin Islands, Guam, the Commonwealth of the Northern 
Mariana Islands, American Samoa, and the possessions of the United 
States.''.
                                 <all>
```
MEMORANDUM 

DATE: December 17, 2014

TO: Clean Power Plan for Existing Power Plants; Docket Id: OAR–2013-0602

FROM: Lora Strine, EPA

SUBJECT: December 17, 2014 Meeting Regarding Proposed Clean Power Plan for Existing 

Power Plants

SUMMARY

A meeting was held between EPA and the Nature Conservancy staff on December 17, 2014 to 

discuss the proposed Clean Power Plan for Existing Power Plants. The Clean Power Plan for 

Existing Power Plants was proposed on June 2, 2014.

ATTENDEES

The Nature Conservancy

Christy Plumer Director of Federal Lands

Len Barson Senior Policy Advisor

US EPA

Ellen Kurlansky Office of Air and Radiation

Matt Clouse Office of Air and Radiation

Lora Strine Office of Air and Radiation
IN THE

TENTH COURT OF APPEALS

No. 10-24-00238-CV

THOMAS B. REED,

Appellant

v.

GIG TOWN PROPERTY MANAGEMENT,

Appellee

From the County Court at Law No. 1

Brazos County, Texas

Trial Court No. 6327-B

MEMORANDUM OPINION

Appellant's docketing statement was due August 20, 2024. In a letter dated 

August 22, 2024, the Clerk of this Court notified appellant that the docketing statement 

was past due and warned appellant that if the docketing statement was not filed within 

21 days from the date of the letter, this appeal would be dismissed without further 

notification. TEX. R. APP. P. 42.3(b), (c) and 44.3. More than 21 days have passed, and the 

docketing statement has not been filed.
Reed v. Gig Town Prop. Mgmt. Page 2

Accordingly, this appeal is dismissed. TEX. R. APP. P. 42.3(c) and 44.3.

TOM GRAY

Chief Justice

Before Chief Justice Gray, 

Justice Johnson, and 

Justice Smith 

Appeal dismissed

Opinion delivered and filed September 26, 2024

[CV06]
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1311 Introduced in House (IH)]

<DOC>

115th CONGRESS
  1st Session
                                H. R. 1311

To amend the Clean Air Act with respect to the ethanol waiver for Reid 
               vapor pressure limitations under such Act.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 2, 2017

 Mr. Smith of Nebraska (for himself, Mr. Loebsack, Mr. Rodney Davis of 
 Illinois, Mr. King of Iowa, Mr. Kinzinger, Mr. Cramer, Mr. Peterson, 
Mr. Pocan, Mr. Cartwright, and Mr. Walz) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
To amend the Clean Air Act with respect to the ethanol waiver for Reid 
               vapor pressure limitations under such Act.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Consumer and Fuel Retailer Choice 
Act''.

SEC. 2. ETHANOL WAIVER.

    (a) Reid Vapor Pressure Limitation.--Section 211(h) of the Clean 
Air Act (42 U.S.C. 7545(h)) is amended--
            (1) in paragraph (4)--
                    (A) in the matter preceding subparagraph (A), by 
                inserting ``or more'' after ``10 percent''; and
                    (B) in subparagraph (C), by striking ``additional 
                alcohol or''; and
            (2) in paragraph (5)(A), by inserting ``or more'' after 
        ``10 percent''.
    (b) Existing Waivers.--Section 211(f)(4) of the Clean Air Act (42 
U.S.C. 7545(f)(4)) is amended--
            (1) by striking ``The Administrator, upon'' and inserting 
        ``(A) The Administrator, upon''; and
            (2) by adding at the end the following:
    ``(B) A fuel or fuel additive that has been granted a waiver under 
subparagraph (A) prior to January 1, 2017, and meets all of the 
conditions of that waiver, other than the waiver's limits for Reid 
Vapor Pressure, may be introduced into commerce if the fuel or fuel 
additive meets all other applicable Reid Vapor Pressure 
requirements.''.
                                 <all>
```
#### In re F.G.M. ASSOCIATES, INC., Debtor. F.G.M. ASSOCIATES, INC., Plaintiff, Appellee, v. CITY OF EAST PROVIDENCE, Defendant, Appellant.

Bankruptcy No. 82-9010.

United States Bankruptcy Appellate Panel for the First Circuit.

July 12, 1982.

Nathaniel Rendine, Asst. City Sol. for East Providence, R. I., for defendant, appellant.

Before LAWLESS, Chief Judge, and GLENNON and LAVIEN, Bankruptcy Judges.

ORDER OF REMAND

PER CURIAM.

The Appellant, the City of East Providence, appeals from an order entered by the Bankruptcy Court for the District of Rhode Island Bkrtcy., 17 B.R. 765 which preliminarily enjoined the City of East Providence from refusing to renew the liquor license of the Debtor, F.G.M. Associates, Inc.

The bankruptcy court entered the preliminary injunction on February 19, 1982, pending a determination of state court appeal by the debtor of the refusal to renew the liquor license.

The panel has been advised of two significant changes in circumstances since the initial order of the bankruptcy court. These circumstances are:

(1) The Chapter 11 has been converted to a Chapter 7.

(2) The Chapter 7 trustee has advised the panel that he does not plan to pursue the state court appeal.

These changes in circumstances may now moot the need for the restraining order. Therefore, we remand this proceeding to the bankruptcy court so the court may, within the next 45 days, dissolve the preliminary injunction or make additional findings which would support a continuation of the injunction.
Exhibit
32.1




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002




In
connection with the Quarterly Report on Form 10-Q of INSIGNIA SOLUTIONS
PLC (the “Company”) for the quarter ended September 30, 2008, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”),
the undersigned, Peter Engel, Chief Executive Officer of the Company hereby
certifies, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the
Sarbanes-Oxley Act of 2002, that:




(1)           The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and




(2)           The
information contained in the Report fairly presents, in all material respects,
the financial condition and result of operations of the Company.




By:
              /s/Peter EngelPeter
      EngelChief
      Executive OfficerMarch
      19, 2009
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AT MARCH 31, 1998 (UNAUDITED) AND THE STATEMENT OF OPERATIONS FOR THE
QUARTERLY PERIOD ENDED MARCH 31, 1998 (UNAUDITED) AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS INCLUDED AS PART OF ITS
QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD MARCH 31, 1998
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                       1,411,759
<SECURITIES>                                         0
<RECEIVABLES>                                  529,959
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,941,718
<PP&E>                                      26,707,030
<DEPRECIATION>                               2,828,283
<TOTAL-ASSETS>                              25,988,569
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  25,988,569
<TOTAL-LIABILITY-AND-EQUITY>                25,988,569
<SALES>                                              0
<TOTAL-REVENUES>                               713,301
<CGS>                                                0
<TOTAL-COSTS>                                  417,169
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   320,780
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
[Federal Register Volume 80, Number 13 (Wednesday, January 21, 2015)]
[Notices]
[Page 3015]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-00887]


-----------------------------------------------------------------------

DEPARTMENT OF VETERANS AFFAIRS


Secretary of Veterans Affairs Advisory Committee Chairs Summit; 
Notice of Meeting

    The Department of Veterans Affairs (VA) gives notice under the 
Federal Advisory Committee Act, 5 U.S.C. App. 2 that the Secretary of 
Veterans Affairs will host a Secretary of Veterans Affairs Advisory 
Committee Chairs Summit on March 13, 2015, at the Department of 
Veterans Affairs Central Office, 810 Vermont Avenue NW., Washington, 
DC. The Summit will be held in the Sonny Montgomery Conference Room 230 
and will convene at 11:00 a.m. and adjourn at 12:30 p.m. The meeting is 
open to the public. Anyone attending must show a valid photo ID to 
building security and be escorted to the meeting. Please allow 15 
minutes before the meeting begins for this process.
    The purpose of the Summit is to enhance the trusting relationship 
between the Secretary and VA's Advisory Committee Chairs, which is 
built on collaboration, I-Care, and the Secretary's vision of MyVA.
    The group will feature remarks from the Secretary and discussion 
with him and the Committee Chairs. Attendees will include VA's Chief of 
Staff and other senior leadership as well as the Designated Federal 
Officer of each Committee. The discussion will focus on strategic 
advisory committee complexities, such as producing reasonable and 
actionable recommendations.
    Although there will be no time for public comment at the meeting, 
interested individuals may submit a 1-2 page statement through March 
27, 2015, to Jeffrey Moragne, Director, Advisory Committee Management 
Office (00AC), 810 Vermont Avenue NW., Washington, DC 20420, or by 
email at <a href="/cdn-cgi/l/email-protection#99cfd8b7d8fdeff0eaf6ebe0b7daf4edfcd9eff8b7fef6ef"><span class="__cf_email__" data-cfemail="96c0d7b8d7f2e0ffe5f9e4efb8d5fbe2f3d6e0f7b8f1f9e0">[email protected]</span></a>. Any member of the public seeking 
additional information should contact Mr. Moragne at (202) 266-4660.

    Dated: January 15, 2015.
Rebecca Schiller,
Federal Advisory Committee Management Officer.
[FR Doc. 2015-00887 Filed 1-20-15; 8:45 am]
BILLING CODE 8320-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>